Journal of Dermatology最新文献

{"title":"Postauricular Skin Mycobiome Profiles in Atopic Dermatitis Treated With Dupilumab or Cyclosporine A: A Descriptive Case Series","authors":"Yuta Koike,&nbsp;Hitomi Morisaki,&nbsp;Daisuke Motooka,&nbsp;Mai Matsumoto,&nbsp;Motoi Takenaka,&nbsp;Hiroyuki Murota","doi":"10.1111/1346-8138.70083","DOIUrl":"10.1111/1346-8138.70083","url":null,"abstract":"<p>Atopic dermatitis (AD) essentially exhibits dysbiosis of skin fungal microbiome, mycobiome, characterized by depletion of <i>Malassezia</i>. The effects of recent systemic therapies for AD on skin mycobiome were not understood enough. We examined changes of skin mycobiome before and after systemic treatments with anti-IL-4Rα antibody (dupilumab: DUP) and calcineurin inhibitor (cyclosporine, CyA). Swab samples from postauricular areas in 19 AD patients treated with dupilumab (<i>n</i> = 13) and cyclosporine (<i>n</i> = 6) were collected before and 4–8 weeks after starting each treatment. Fungal DNA was amplified from the samples and sequenced with ITS1 metagenomic analysis, and taxonomic classification was performed. Fungi belonging to total 89 genera were detected. The share of the fungus was most occupied by <i>Malassezia</i> (81.3%), followed by <i>Aspergillus</i> (3.7%), and <i>Trametes</i> (1.1%) before DUP and CyA treatment, and occupied by <i>Malassezia</i> (87.3%), followed by <i>Aspergillus</i> (1.9%), and <i>Candida</i> (1.7%) after treatment. Three AD patients whose ratio of <i>Malassezia</i> in the skin mycobiome was under 50%, showed an exploratory increase of <i>Malassezia</i> after treatments (before 17.3%, after 67%). Analysis of the <i>Malassezia</i> species revealed an increase in <i>M. restricta</i> (before 70.5%, after 79.5%) and a decrease in <i>M. globosa</i> (before 23.9%, after 16.1%). No consistent patterns distinguishing DUP and CyA were observed. Systemic treatment with DUP and CyA was associated with shifts toward higher <i>Malassezia</i> abundance and modulation between <i>M. restricta</i> and <i>M. globosa.</i> These findings are exploratory and require validation in larger controlled studies.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 3","pages":"430-436"},"PeriodicalIF":2.7,"publicationDate":"2026-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12967678/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145644388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Barriers to Accurate Diagnosis of Infantile Atopic Dermatitis: Insights From a Survey of Pediatricians","authors":"Kiwako Yamamoto-Hanada,&nbsp;Yasusuke Kawada,&nbsp;Kana Okamoto,&nbsp;Miyuki Matsukawa,&nbsp;Takahiro Tsuchiya,&nbsp;Daisaku Michikami,&nbsp;Yukihiro Ohya","doi":"10.1111/1346-8138.70052","DOIUrl":"10.1111/1346-8138.70052","url":null,"abstract":"<p>Accurate diagnosis is essential for timely intervention in atopic dermatitis (AD), yet delays in diagnosis remain common. To better understand current clinical practices regarding infantile AD, a questionnaire survey was conducted among Japanese pediatricians working at medical institutions with 19 or fewer beds. Respondents who provided informed consent completed an online questionnaire that included items on screening practices, physician background, understanding of diagnostic and treatment practices, and recognition of key clinical issues. In total, 238 valid responses were analyzed. Most respondents indicated that they were non-allergists (85.7% of responses), aged 50 years or older (68.9% of responses) and reported high clinical experience in treating infantile eczema. Only 44.1% of respondents correctly recognized that AD is a condition within the collective term of infantile eczema. Almost all (92.0%) respondents correctly agreed that early intervention was effective for infantile AD and most recognized that AD treatment is prolonged, that AD induces other allergic diseases, and that AD is unlikely to resolve spontaneously in most cases. Understanding of the primary nature of AD was poor with 62.6% of respondents either incorrectly stating that AD is caused by other allergic diseases or that they did not know. The mean (SD) minimum age of AD diagnosis was 7.4 (4.81) months (median, 6.0 months) and 23.9% of physicians diagnosed AD after 1 year of age. Only 16.4% of respondents correctly identified a case of infantile AD and only 19.3% of respondents correctly selected the most appropriate treatment for a known case of infantile AD. Reluctance to inform parents/caregivers of an AD diagnosis was high and mostly due to anticipation of parental shock. Certain pediatricians in Japan have misunderstandings about infantile AD. Further awareness of infantile AD is necessary to ensure early diagnosis and intervention as well as management aligned with guideline recommendations.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 3","pages":"421-429"},"PeriodicalIF":2.7,"publicationDate":"2026-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12967741/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145524792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety Evaluation of Fine Bubble Shower Washing for Patients With Atopic Dermatitis: A Double-Blind, Randomized, Prospective Crossover Clinical Trial","authors":"Hiroshi Kato,&nbsp;Risa Tamagawa-Mineoka,&nbsp;Eiji Nakatani,&nbsp;Kenichi Yoshimura,&nbsp;Yukiko Yasui,&nbsp;Kasumi Kato,&nbsp;Motoki Nakamura,&nbsp;Ako Kurachi,&nbsp;Soshi Takeda,&nbsp;Akimichi Morita","doi":"10.1111/1346-8138.70117","DOIUrl":"10.1111/1346-8138.70117","url":null,"abstract":"<p>Atopic dermatitis (AD) involves chronic eczema resulting from barrier dysfunction. Fine bubble (FB) technology generates microbubbles (&lt; 100 μm) and ultrafine bubbles (&lt; 1 μm) for surfactant-sparing cleansing. We assessed the short-term safety of an FB shower in AD. In this double-blind, randomized, crossover study, adults with mild AD completed two 2-week periods separated by a 2-week washout in sequence. Bathing instructions and petrolatum moisturizer use were standardized and enforced. The Eczema Area and Severity Index (EASI) was scored using whole-body photographs by a blinded team. Transepidermal water loss (TEWL) and stratum corneum hydration were measured on Days 0, 14, and 28. Because baselines were unavailable for the second 2-week period, the primary analysis compared Day 0–14 changes between groups using baseline-adjusted analysis of covariance; Day 0–28 changes were also explored. The primary outcomes were EASI changes; TEWL and hydration were the secondary outcomes. Groups used a conventional shower (control) first and then FB shower second or vice versa (once each). Twenty-three participants were analyzed (mean age 40.9 ± 8 years; 83% male). Day 0–14 EASI changes did not differ between FB and control (0.62 ± 2.21 vs. 0.05 ± 0.68; F = 0.93, <i>p</i> = 0.35). EASI changes to Day 28 were nonsignificant (0.02 ± 1.65 vs. −0.03 ± 1.02; <i>p</i> = 0.90). TEWL changes for Days 0–14 (0.31 ± 4.75 vs. 1.09 ± 6.21 g/m²/h) and to Day 28 (5.49 ± 14.43 vs. −0.27 ± 5.28 g/m²/h) showed no between-group differences. Hydration changes were similar for Days 0–14 (5.53 ± 13.23 vs. 6.14 ± 7.96 AU) and to Day 28 (18.41 ± 10.33 vs. 21.09 ± 11.07 AU). No serious adverse events or discontinuations for worsening symptoms occurred. Under standardized, low-irritant conditions, the FB shower was well-tolerated by adults with mild AD and did not worsen severity or barrier indices over 4 weeks. However, the superiority of FB to a conventional shower was not demonstrated.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 3","pages":"447-453"},"PeriodicalIF":2.7,"publicationDate":"2026-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12967768/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145770000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Maintenance of Early Responses and Achievement of Delayed Responses to Deucravacitinib Treatment in Psoriais: A 104-Week Real-World Study in Japan","authors":"Hiroki Usuki,&nbsp;Teppei Hagino,&nbsp;Yohei Takahashi,&nbsp;Hidehisa Saeki,&nbsp;Eita Fujimoto,&nbsp;Naoko Kanda","doi":"10.1111/1346-8138.70139","DOIUrl":"10.1111/1346-8138.70139","url":null,"abstract":"<div>\u0000 \u0000 <p>The tyrosine kinase 2 inhibitor deucravacitinib is effective for psoriasis. However, it is unclear whether early responses to deucravacitinib in real-world practice are maintained for 2 years and whether patients without early responses can achieve delayed responses. This study is aimed to evaluate the sustainability of week 16 responses to deucravacitinib treatment for psoriasis and to evaluate delayed responses in week 16 poor responders. This prospective study included 117 Japanese patients with moderate-to-severe psoriasis treated with deucravacitinib. Patients who achieved psoriasis area and severity index (PASI) 75, PASI 90, PASI 100, absolute PASI ≤ 2, absolute PASI ≤ 1, static physician's global assessment (sPGA) 0/1, or dermatology life quality index (DLQI) 0/1 at week 16 were evaluated for maintenance of each outcome. Patients who did not achieve these outcomes at week 16 were evaluated for delayed achievement of each outcome through week 104. In week 16 achievers, week 104 maintenance rates of PASI 75, PASI 90, PASI 100, absolute PASI ≤ 2, and absolute PASI ≤ 1 were 95.2%, 87.5%, 66.7%, 100%, and 91.7%, respectively, while those of sPGA 0/1 and DLQI 0/1 were 100% and 88.9%, respectively. In week 16 non-achievers, week 104 achievement rates for PASI 75, PASI 90, PASI 100, absolute PASI ≤ 2, and absolute PASI ≤ 1 were 25.0%, 15.4%, 7.7%, 50.0%, and 23.5%, respectively, and those for sPGA 0/1 and DLQI 0/1 were 60.0% and 50.0%, respectively. Improvements of rash and quality of life achieved at week 16 of deucravacitinib treatment were mostly sustained through week 104. Some patients without week 16 responses could achieve delayed responses at later time points.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 3","pages":"506-513"},"PeriodicalIF":2.7,"publicationDate":"2026-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145902054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Characteristics and Risk Factors for Cutaneous Manifestations Associated With Nemolizumab in Atopic Dermatitis: A Multicenter Retrospective Study in Japan","authors":"Wataru Sasaki,&nbsp;Ryo Saito,&nbsp;Kenta Suzuki,&nbsp;Daisuke Watanabe,&nbsp;Masako Minami-Hori,&nbsp;Hirofumi Kamada,&nbsp;Hiroo Amano,&nbsp;Akihiko Uchiyama,&nbsp;Sei-ichiro Motegi,&nbsp;Machiko Kamura,&nbsp;Kazunari Sugita,&nbsp;Noriko Kubota,&nbsp;Toshifumi Nomura,&nbsp;Maki Ozawa,&nbsp;Toshiya Takahashi,&nbsp;Takashi Yamakita,&nbsp;Kazumitsu Sugiura,&nbsp;Tetsuharu Ikegami,&nbsp;Ken Igawa,&nbsp;Yuka Kimura,&nbsp;Yoko Kataoka,&nbsp;Ryoichi Kamide,&nbsp;Masakazu Takahashi,&nbsp;Akio Tanaka,&nbsp;Mariko Sugawara-Mikami","doi":"10.1111/1346-8138.17877","DOIUrl":"10.1111/1346-8138.17877","url":null,"abstract":"<p>Nemolizumab, an anti-interleukin-31 receptor A monoclonal antibody, has been approved in Japan for treating atopic dermatitis (AD)-associated pruritus. While it is effective for itch control, nemolizumab-associated cutaneous adverse events have been increasingly recognized, yet their clinical features remain poorly characterized. In this study, we aimed to investigate the incidence, clinical characteristics, and timing of cutaneous manifestations associated with nemolizumab treatment in patients with AD, and to explore potential associations with baseline disease severity and immunological parameters. We conducted a multicenter retrospective study involving 219 patients aged ≥ 13 years with AD who received nemolizumab at 13 institutions in Japan between August 2022 and February 2024. Cutaneous eruptions were classified into six categories based on clinical consensus. Patients who received fewer than three doses without developing skin reactions were excluded. Clinical and laboratory parameters were compared between patients with and without cutaneous manifestations. Cutaneous manifestations occurred in 88 patients (40.2%), most commonly within the first three doses. Erythema was the most frequent presentation (69.3%), and 62.5% of eruptions were non-pruritic. No significant associations were observed between the occurrence of skin reactions and baseline eczema area and severity index scores, eosinophil counts, serum immunoglobulin E, or thymus and activation-regulated chemokine levels. Two cases of bullous pemphigoid were identified. Despite topical corticosteroid treatment, nemolizumab therapy was discontinued in 42% of the patients affected. In conclusion, nemolizumab frequently induces early-onset, morphologically distinct cutaneous eruptions that appear to be independent of baseline disease severity or biomarkers.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 3","pages":"399-409"},"PeriodicalIF":2.7,"publicationDate":"2026-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12967727/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144692918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Efficacy of Chemotherapy in Patients With Advanced Unresectable Extramammary Paget Disease: A Retrospective Multicenter Study of 138 Japanese Patients","authors":"Azusa Miyashita,&nbsp;Satoshi Fukushima,&nbsp;Koji Yoshino,&nbsp;Hiroshi Kato,&nbsp;Naoya Yamazaki,&nbsp;Shusuke Kawashima,&nbsp;Yuki Yamamoto,&nbsp;Yasuhiro Nakamura,&nbsp;Yukiko Kiniwa,&nbsp;Shoichiro Ishizuki,&nbsp;Takeo Maekawa,&nbsp;Etsuko Okada,&nbsp;Taku Fujimura,&nbsp;Kazuyasu Fujii,&nbsp;Yasuhiro Fujisawa,&nbsp;Jun Asai,&nbsp;Atsushi Otsuka,&nbsp;Ikko Kajihara,&nbsp;Jun Morinaga,&nbsp;Shigeto Matsushita","doi":"10.1111/1346-8138.70125","DOIUrl":"10.1111/1346-8138.70125","url":null,"abstract":"<div>\u0000 \u0000 <p>Extramammary Paget disease (EMPD) is a rare skin cancer with an estimated incidence rate of 0.13 per 100 000 population/year in Caucasians and 0.28 in Asians. Although distant metastases have been reported in 10%–20% of EMPD cases, standardized systemic chemotherapy has not been established. Prospective clinical trials are essential to establish standard treatments for advanced EMPD. Therefore, this retrospective study examined a substantial number of patients with EMPD to assess the efficacy of systemic chemotherapy. This study included 164 patients with advanced EMPD who underwent treatment at 16 Japanese institutions. Treatment efficacy was evaluated in a cohort of 138 patients, after excluding 26 patients without lesions outside the radical irradiation field from the 164 patients. The efficacy of each treatment was evaluated by determining the objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) using Kaplan–Meier analysis. Multivariate analysis was performed to account for potential confounding factors, such as age, sex, and performance status. The patients received the following treatments: docetaxel hydrate (DOC) (65.9%); tegafur/gimeracil/oteracil potassium, DOC (S-1/DOC) (9.8%); fluorouracil and cisplatin (FP) (15.9%); and other drugs (8.5%). DOC is the most commonly used in Japan. The ORRs in the DOC, S-1/DOC, and FP groups were 51.6%, 78.6%, and 27.8%, respectively. Logistic regression analysis revealed that, compared with the DOC group, the odds ratio for the ORR of the S-1/DOC group was 3.29 (95% CI: 1.49–7.25, <i>p</i> = 0.003). However, no significant differences in OS or PFS were observed between the treatment groups (<i>p</i> = 0.122 and <i>p</i> = 0.422, respectively). This study provides valuable information on EMPD and may serve as a useful historical control for the future evaluation of new treatments for EMPD.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 3","pages":"478-487"},"PeriodicalIF":2.7,"publicationDate":"2026-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145866883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Profiles of Psoriasis Patients With Coronary Artery Calcification and Assessment of Acute Coronary Syndrome Risk Factors Using Coronary Computed Tomography Angiography-Estimated Fractional Flow Reserve","authors":"Hidenori Watabe,&nbsp;Yuki Ishibashi,&nbsp;Ken Go,&nbsp;Kaori Nakajima,&nbsp;Yasuhiro Tanabe,&nbsp;Yoshihiro J. Akashi,&nbsp;Takafumi Kadono,&nbsp;Tomomitsu Miyagaki","doi":"10.1111/1346-8138.70133","DOIUrl":"10.1111/1346-8138.70133","url":null,"abstract":"<div>\u0000 \u0000 <p>Psoriasis is frequently associated with comorbidities such as metabolic syndrome and acute coronary syndrome (ACS). Coronary artery calcification (CAC), an independent predictor of coronary events, has been reported to be more prevalent in psoriasis patients than in healthy controls. However, its clinical significance and relationship with ACS risk in psoriasis remain incompletely understood. We conducted a single-center retrospective cross-sectional study involving 89 Japanese patients with psoriasis who underwent chest computed tomography (CT) to assess the presence of CAC. In selected patients with CAC, coronary CT angiography (CCTA) was performed, and the fractional flow reserve derived from CT (FFR_CT) was calculated. Thirty-one patients with CAC were more likely to have psoriasis vulgaris, were older, had lower estimated glomerular filtration rates (eGFR), and exhibited higher hemoglobin A1c (HbA1c) levels compared with those without CAC. Among the 22 patients who underwent CCTA, coronary artery calcium scores (CACS) were positively correlated with Psoriasis Area and Severity Index (PASI) scores, serum C-reactive protein (CRP), and HbA1c levels. FFR_CT was measured in 10 patients with ≥ 40% coronary stenosis; six had FFR_CT value ≤ 0.80, indicating a high risk of ACS. Multivariable logistic regression analysis using a stepwise selection method identified age as the only significant predictor of ACS risk. In conclusion, elderly psoriasis patients with concomitant diabetes mellitus (DM) may have an elevated risk of ACS and could benefit from cardiology referral for cardiovascular risk assessment.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 3","pages":"488-495"},"PeriodicalIF":2.7,"publicationDate":"2026-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145901814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spatial and Temporal Summation of Histaminergic and Non-Histaminergic Itch","authors":"Giulia Erica Aliotta,&nbsp;Silvia Lo Vecchio,&nbsp;Ryusuke Tanaka,&nbsp;Nicoline Stampe Batsberg,&nbsp;Sine Duch-Svenson,&nbsp;Emilie Spagner Fernández,&nbsp;Mohammad Ali Hafiz,&nbsp;Nick Torp Holm,&nbsp;Kristian Herman Ladegaard,&nbsp;Meenuya Rajhmohan,&nbsp;Jesper Elberling,&nbsp;Lars Arendt-Nielsen","doi":"10.1111/1346-8138.70130","DOIUrl":"10.1111/1346-8138.70130","url":null,"abstract":"<div>\u0000 \u0000 <p>Chronic itch represents a social burden due to its high prevalence, negative impact on quality of life, and limited treatment options. Spatial (simultaneously applied stimuli at multiple skin sites) and temporal (repeated stimuli over time) summation are key mechanisms in itch processing but have not been investigated in detail in humans. This study assessed experimentally induced histaminergic and non-histaminergic itch provocations in healthy volunteers. In the spatial summation experiment, histamine or cowhage was applied in randomized order to one area, two areas on the same arm, or two areas on different arms. Itch and pain intensities were recorded for 9 min, followed by assessment of alloknesis and hyperknesis. In the temporal summation experiment, each pruritogen was applied either once or repeatedly at intervals of 90 or 180 s apart to the forearm. Itch and pain intensities were recorded for 15 min, after which superficial blood perfusion (SBP), alloknesis, and hyperknesis were assessed. Itch intensity and calculated area under the curve (AUC) were significantly facilitated by special summation after both ipsilateral and contralateral applications of both pruritogens. Temporal summation significantly increased AUC after reapplication of either of the pruritogens after 180 s. Reapplication after 90 s significantly increased cowhage-induced SBP, while reapplication after 180 s increased histamine-induced SBP. In conclusion, spatial summation augmented itch intensity and AUC, whereas temporal summation increased AUC and enhanced SBP. Both effects were observed for histaminergic and non-histaminergic itch, highlighting differences in fundamental mechanisms.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 3","pages":"518-523"},"PeriodicalIF":2.7,"publicationDate":"2026-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145919438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stratum Corneum Ceramide Abnormalities in Atopic Dermatitis: Pathophysiology and Implications for Disease Management","authors":"Takashi Sakai","doi":"10.1111/1346-8138.70098","DOIUrl":"10.1111/1346-8138.70098","url":null,"abstract":"<p>The stratum corneum, as the outermost layer of the skin, functions as a critical barrier that maintains cutaneous hydration and systemic homeostasis. Among its structural lipids, ceramides constitute the most abundant and diverse component. These molecules are essential for the formation of lamellar structures that secure barrier integrity. Increasing evidence has established that abnormalities in stratum corneum ceramides are not merely epiphenomena but fundamental contributors to the pathophysiology of atopic dermatitis (AD). In this review, we provide an overview of the structure, biosynthesis, and diversity of ceramides within the stratum corneum, followed by a discussion of their pivotal role in skin barrier function. We highlight recent insights into how ceramide abnormalities manifest in AD, including reduced total content, altered class distribution, and a shift toward shorter-chain fatty acids. Such alterations are associated with increased transepidermal water loss and impaired hydration. Mechanistic studies further reveal that type 2 cytokines, particularly IL-4 and IL-13, directly disrupt lipid metabolism by inhibiting enzymes, thereby establishing a vicious cycle of inflammation and barrier dysfunction. Beyond pathophysiology, advances in lipidomics and tape-stripping techniques now enable noninvasive assessment of stratum corneum ceramides. These analyses have revealed their utility as biomarkers of disease activity, therapeutic response, and relapse risk. Collectively, ceramides of the stratum corneum provide a unique window into the biology of AD. Their accessibility, mechanistic relevance, and prognostic potential underscore their importance not only for understanding disease pathogenesis but also for advancing personalized management and the concept of disease modification in AD.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 3","pages":"380-387"},"PeriodicalIF":2.7,"publicationDate":"2026-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12967696/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145764820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term, Site-Specific Effectiveness of Tralokinumab in Atopic Dermatitis: A 72-Week Real-World Study","authors":"Mizuki Shiba,&nbsp;Teppei Hagino,&nbsp;Akihiko Uchiyama,&nbsp;Hidehisa Saeki,&nbsp;Eita Fujimoto,&nbsp;Sei-ichiro Motegi,&nbsp;Naoko Kanda","doi":"10.1111/1346-8138.70138","DOIUrl":"10.1111/1346-8138.70138","url":null,"abstract":"<p>Tralokinumab, an anti-IL-13 antibody, is effective for atopic dermatitis (AD); however, its long-term (&gt; 1 year) effectiveness specific to each anatomical site is unknown in real-world settings. To evaluate 72-week effectiveness of tralokinumab on different anatomical sites in AD, we studied 208 patients with moderate-to-severe AD treated with tralokinumab for 72 weeks. Eczema area and severity index (EASI) scores were analyzed on four anatomical sites (head/neck, trunk, upper limbs, and lower limbs). Tralokinumab consistently reduced EASI on all anatomical sites. The achievement rates of EASI 75 and 100 on each site gradually increased from Week 4 to Week 72, and those on lower limbs appeared higher compared to the other sites. The percent reductions of EASI throughout 72 weeks appeared slightly lower on head and neck compared to the other sites. Week 72 achievement rate of EASI 75 on head/neck, trunk, upper limbs, or lower limbs was 80.4%, 80%, 80.3%, or 86.7%, while that of EASI 100 was 37.3%, 25.0%, 27.4%, and 40.0%, respectively. Tralokinumab reduced EASI scores through 72 weeks across different anatomical sites in AD patients. The achievement rates of EASI 75 and 100 appeared slightly higher on lower limbs compared to the other sites.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 3","pages":"454-460"},"PeriodicalIF":2.7,"publicationDate":"2026-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12967683/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145902068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}